Abstract:Retrospective clinical studies and case reports have found that the abscopal effect of radiotherapy (RT) may be increased by the addition of immunotherapy. This study sought further evidence for such a synergistic abscopal effect by combining RT and immunotherapy in a murine tumor model. Forty-two immunocompetent KRAS-LSL-G12D/+/p53KO mice were implanted with syngeneic KP-1 tumor cells in both the upper and lower back and randomized into seven groups. Group 1 controls were administered sham treatment. Group 2 received radiation with 8 Gy x 3 fractions delivered to the lower back tumors only. Groups 3 and 4 were given 250 μg of murine anti-PD-1 monoclonal antibody as either an intraperitoneal (IP) or intratumoral (IT) injection to lower back tumors only. Groups 5, 6 and 7 received both RT to the lower back tumors and anti-PD-1 antibody delivered either as an IP injection (250 μg) or an IT injection (250 μg or 500 μg) to lower back tumors only. Tumor growth was measured at both the non-irradiated (upper back) site and the irradiated (lower back) site. Irradiated lower back tumors demonstrated a smaller increase in mean tumor volume for mice receiving radiation (RT = 62 mm3) or RT and immunotherapy (RT+IP = 37 mm3, RT+ 250 μg IT = 37 mm3, RT + 500 μg IT = 84 mm3) than for mice receiving either no treatment (sham = 286 mm3, p <0.05) or anti-PD-1 antibody alone (IP = 155 mm3, 250 μg IT = 288 mm3; p < 0.05, Table 1). Immunotherapy alone did not alter the mean growth of non-irradiated upper back tumors (IP = 407 mm3, 250 μg IT = 643 mm3, sham = 559 mm3). The combination of RT with 250 μg IT anti-PD-1 antibody (but not 500 μg) produced decreased growth of upper back tumors from day 1 to day 11 (165 mm3 vs sham = 449 mm3, p = 0.018), an early trend which was reversed by an increase in upper back tumor volume from day 11 to day 15 (Table 1). For all groups, body weight did not change significantly throughout the trial. The results demonstrate a growth delay of murine KP-1 tumors when treated with RT alone or in combination with immunotherapy. Evidence for a synergistic abscopal effect is provided by an early trend toward improved control of non-irradiated tumors when lower-dose IT immunotherapy is combined with irradiation at a remote tumor site but not when either treatment is given alone.Abstract 3150; Table 1Mean tumor volume (mm3)Lower back tumor (irradiated)Upper back tumor (non-irradiated)Day14811151481115Control98144206283384228359517677787RT only155157150201217238309462619789IP104131187240259223266398442630IT105141227292393235400532732878RT + IP11611790130153223248362529785RT + 250 μg IT111109117106148217208257382614RT + 500 μg IT116109140148200207241320498622 Open table in a new tab

Combination of radiotherapy and suppression of Tregs enhances abscopal antitumor effect and inhibits metastasis in rectal cancer

Effect of hypofractionated radiotherapy, PD-1 immunotherapy, and anti-angiogenic therapy on abscopal responses and the tumor microenvironment.

Pivotal roles of tumor‐draining lymph nodes in the abscopal effects from combined immunotherapy and radiotherapy

Radiotherapy-Mediated Immunomodulation and Anti-Tumor Abscopal Effect Combining Immune Checkpoint Blockade

Combination low-dose cyclophosphamide with check-point blockade and ionizing radiation promote an abscopal effect in mouse models of melanoma

Antiangiogenic Treatment Facilitates the Abscopal Effect of Radiation Therapy Combined With Anti-PD-1 in Hepatocellular Carcinoma

Effect of Low-Dose Radiotherapy on Abscopal Responses to Hypofractionated Radiotherapy and Anti-Pd1 in Mice and NSCLC Patients.

Abscopal effect of radiotherapy combined with immune checkpoint inhibitors

Brachytherapy attains abscopal effects when combined with immunostimulatory monoclonal antibodies

Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy

Radiotherapy combined with immunotherapy could improve the immune infiltration of melanoma in mice and enhance the abscopal effect

Abscopal Effects of Local Radiotherapy Are Dependent on Tumor Immunogenicity

Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer

Cytoreductive Nephrectomy Promoted Abscopal Effect of Camrelizumab Combined With Radiotherapy for Metastatic Renal Cell Carcinoma: A Case Report and Review of the Literature

Α-Pd-l1 Mab Enhances the Abscopal Effect of Hypo-Fractionated Radiation by Attenuating PD-L1 Expression and Inducing CD8+T-cell Infiltration

Synergistic Expression of the Abscopal Effect in a Murine Tumor Model Treated with Combined Radiation and Single or Dual-Immune Checkpoint Blockade

Combination of Radiotherapy and PD-L1 Blockade Induces Abscopal Responses in EGFR-mutated Lung Cancer Through Activating CD8+ T Cells

ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer

CD169-positive macrophages enhance abscopal effect of radiofrequency ablation therapy in liver cancer

Radiotherapy Enhances Metastasis Through Immune Suppression by inducing PD-L1 and MDSC in distal sites

Tregs ST2 deficiency enhances the abscopal anti-tumor response induced by microwave ablation